H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Outlook Therapeutics (OTLK) to $3 from $30 and keeps a Buy rating on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback